Skip to search formSkip to main content
You are currently offline. Some features of the site may not work correctly.

New Agents

Research into new physical or chemical means to treat disease.
National Institutes of Health

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2019
2019
Survival Outcomes From a Cumulative Analysis of Worldwide Observational Studies on Sequential Use of New Agents in Metastatic Castration-Resistant Prostate Cancer.
INTRODUCTION The sequential use of a number of new agents (NAs) have improved the overall survival (OS) of patients with… Expand
2018
2018
Impact of new agents (NAs) on survival of metastatic castration-resistant prostate cancer (mCRPC) patients (pts): A single-Institution retrospective analysis.
323Background: Until few years ago, docetaxel (DOC) was the only agent able to significantly prolong overall survival (OS) of… Expand
2017
2017
Outcomes of metastatic castration-resistant prostate cancer (mCRPC) patients (pts) treated with different new agents (NAs) sequence in post-docetaxel (DOC) setting: Final analysis from a multicenter…
5030Background: Abiraterone acetate (AA), cabazitaxel (CABA), and enzalutamide (ENZ) may prolong survival in mCRPC pts… Expand
Review
2015
Review
2015
Sequencing new agents after docetaxel in patients with metastatic castration-resistant prostate cancer.
BACKGROUND Two new hormonal agents (NHAs), abiraterone and enzalutamide, and one chemotherapeutic agent, cabazitaxel (CABA… Expand
2015
2015
Sequential use of new agents (NAs) after docetaxel (DOC) first line in metastatic castration-resistant prostate cancer (mCRPC) patients (pts): A pooled-analysis of the published studies.
258 Background: NAs have recently demonstrated a survival advantage in mCRPC pts progressing after DOC: two hormonal NAs (HNA… Expand
2014
2014
Impacts of new agents for multiple myeloma on development of secondary myelodysplastic syndrome and acute myeloid leukemia.
The use of new agents (NAs) such as bortezomib, thalidomide, and lenalidomide has extended the survival of patients with multiple… Expand
Review
2014
Review
2014
Lupus nephritis: the evolving role of novel therapeutics.
  • B. Rovin, S. Parikh
  • American journal of kidney diseases : the…
  • 2014
    • Corpus ID: 8607075
Immune complex accumulation in the kidney is the hallmark of lupus nephritis and triggers a series of events that result in… Expand
  • figure 1
  • table 1
  • figure 2
Highly Cited
2013
Highly Cited
2013
Evolving risk of therapy-related acute myeloid leukemia following cancer chemotherapy among adults in the United States, 1975-2008.
Therapy-related acute myeloid leukemia (tAML) is a rare but highly fatal complication of cytotoxic chemotherapy. Despite major… Expand
  • figure 1
  • figure 2
  • table 1
  • table 2
  • table 3
2012
2012
Lenalidomide in myeloma--a high-maintenance friend.
  • A. Badros
  • The New England journal of medicine
  • 2012
    • Corpus ID: 45266721
With the introduction of high-dose therapy and new agents, outcomes of treatment have improved considerably for patients with… Expand
1984
1984
Placebo-controlled clinical trials in gastroenterology. A position paper of the American College of Gastroenterology.
  • D. Sachar
  • The American journal of gastroenterology
  • 1984
    • Corpus ID: 22468260
Treatment programs for digestive diseases should be evaluated by randomized clinical trials. Under most circumstances, the best… Expand
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy, Terms of Service, and Dataset License
ACCEPT & CONTINUE